SI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Alliancebernstein L.P.

Alliancebernstein L.P. boosted its holdings in SI-BONE, Inc. (NASDAQ:SIBN) by 6.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,750 shares of the company’s stock after purchasing an additional 3,250 shares during the quarter. Alliancebernstein L.P. owned about 0.13% of SI-BONE worth $782,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. American Century Companies Inc. lifted its position in shares of SI-BONE by 11.0% during the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company’s stock worth $33,341,000 after buying an additional 236,167 shares during the last quarter. State Street Corp lifted its position in SI-BONE by 5.1% in the third quarter. State Street Corp now owns 1,081,871 shares of the company’s stock valued at $15,125,000 after acquiring an additional 52,972 shares during the last quarter. Geode Capital Management LLC boosted its stake in SI-BONE by 3.4% in the third quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock valued at $12,921,000 after acquiring an additional 30,005 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in SI-BONE by 35.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company’s stock valued at $11,791,000 after acquiring an additional 220,555 shares in the last quarter. Finally, Impax Asset Management Group plc grew its holdings in shares of SI-BONE by 1.1% during the fourth quarter. Impax Asset Management Group plc now owns 766,761 shares of the company’s stock worth $10,750,000 after purchasing an additional 8,240 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, insider Anthony J. Recupero sold 3,311 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now directly owns 284,555 shares in the company, valued at approximately $4,026,453.25. The trade was a 1.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now owns 244,878 shares of the company’s stock, valued at $3,462,574.92. This represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,776 shares of company stock valued at $96,644. 3.90% of the stock is owned by corporate insiders.

SI-BONE Stock Up 3.9 %

SI-BONE stock opened at $13.85 on Friday. The stock has a market capitalization of $587.97 million, a price-to-earnings ratio of -15.05 and a beta of 1.02. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The stock has a 50 day moving average of $15.27 and a two-hundred day moving average of $14.63. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $49.00 million for the quarter, compared to analysts’ expectations of $48.87 million. As a group, research analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on SIBN shares. Truist Financial reissued a “buy” rating and issued a $22.00 target price (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Needham & Company LLC increased their price objective on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $24.40.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.